Tilrekimig

替锐奇米单抗

Report date: 2026/05/07 20:00:36

Base Information

Drug NameTilrekimig
Drug Alias NamePF-07275315
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-IL13Anti-Interleukin-4Anti-Thymic stromal lymphopoietin
TargetsInterleukin-13Interleukin-4Thymic stromal lymphopoietin
Therapy Area/IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (China) Research And Development Co LtdPfizer IncWyeth BioPharma Division of Wyeth Pharmaceuticals Llc +[4] 
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicPulmonary Disease, Chronic ObstructiveAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A